Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
13/02/2025 13:44
Feb 13 (Reuters) - TC Biopharm (Holdings) PLC T0Uy.F :
* TCBP ANNOUNCES SUCCESSFUL COMPLETION OF COHORT A IN THE
ACHIEVE
CLINICAL TRIAL
* TC BIOPHARM- AVAILABLE DATA SHOW A FAVORABLE SAFETY &
EFFICACY
RESPONSE IN COHORT A PATIENTS, PATIENTS WITH RELAPSE OR
REFRACTORY AML
* TC BIOPHARM (HOLDINGS) PLC - NO DRUG-RELATED ADVERSE
EVENTS IN
COHORT A PATIENTS
Source text: ID:nPn5l9x6Xa
Further company coverage: T0Uy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange